Sermorelin vs CJC-1295
Sermorelin and CJC-1295 are closely related GHRH analogs built on the same GRF(1-29) fragment, which is why they are so often compared. The differences come down to stability, half-life, and regulatory history rather than the underlying receptor target. This comparison walks through how the older, shorter-acting sermorelin stacks up against the engineered, longer-acting CJC-1295.
| Sermorelin | CJC-1295 | |
|---|---|---|
| Class | GHRH analog — GRF(1-29), the shortest fully active GHRH fragment | GHRH analog — a stabilized, modified GRF(1-29) |
| Primary mechanism | Binds the GHRH receptor to stimulate natural GH release | Binds the GHRH receptor; amino-acid substitutions resist enzymatic breakdown |
| Reported half-life | Very short, ~10-20 minutes | No-DAC ~30 minutes; DAC version ~6-8 days |
| Stability / modifications | Unmodified fragment; degraded quickly | Modified (and optionally DAC-bound) for longer action |
| Reported research dosing | ~100-300 mcg per dose in references (historically ~1 mcg/kg as a diagnostic) | No-DAC ~100 mcg per dose; DAC dosed weekly |
| Route / frequency | Subcutaneous, typically nightly | Subcutaneous; no-DAC 1-3x/day, DAC ~1-2x/week |
| Regulatory status | Formerly FDA-approved (Geref), withdrawn for commercial reasons; now via compounding | Never approved; sold as research-use-only |
| Best studied for | GH-axis diagnostics and GH-support protocols | Longer-acting GHRH stimulation in research contexts |
Sermorelin
Sermorelin is the classic GHRH analog — GRF(1-29) — with a very short half-life and a history as the FDA-approved diagnostic Geref (later withdrawn for commercial reasons); it is now typically accessed through compounding pharmacies.
Full Sermorelin profile →CJC-1295
CJC-1295 is a modified, stabilized version of the same GRF(1-29) sequence, engineered to last longer — either a short no-DAC form or a multi-day DAC form — and is sold as a research-use-only compound rather than an approved drug.
Full CJC-1295 profile →The bottom line
Sermorelin and CJC-1295 are closely related GHRH analogs built on the same active fragment; the main practical differences are stability and half-life, plus regulatory status — sermorelin was an approved product and remains available via compounding, whereas CJC-1295 has never been approved and is research-use-only. Neither is a substitute for medical care. This is educational information, not medical advice.
Educational summary only. Dosing and effects describe how these compounds appear in the research literature — not a recommendation for human use. For laboratory research use only.
Sermorelin vs CJC-1295 FAQ
What is the difference between sermorelin and CJC-1295?
Both are GHRH analogs based on the GRF(1-29) fragment, but sermorelin is the unmodified fragment with a very short (~10-20 minute) half-life, while CJC-1295 is chemically modified to resist breakdown and last longer — from about 30 minutes (no-DAC) up to several days (DAC).
Is sermorelin FDA-approved?
Sermorelin was previously FDA-approved as the diagnostic product Geref but was withdrawn from the market for commercial reasons rather than safety; it is now generally obtained through compounding pharmacies. CJC-1295 has never been approved and is sold as research-use-only.
Are sermorelin and CJC-1295 the same thing?
They are close relatives, not identical. CJC-1295 is essentially a stabilized, longer-acting redesign of the GRF(1-29) sequence that sermorelin represents, so they share a receptor target but differ in durability and dosing frequency.
Are sermorelin and CJC-1295 banned in sport?
Yes. As GHRH analogs and growth-hormone secretagogues, both fall under the WADA Prohibited List (S2) and are banned for athletes in and out of competition.